## 1 **Pulsed electromagnetic fields may be effective for the management of primary**

# 2 **osteoporosis: a systematic review and meta-analysis**

3



### 22 **ABSTRACT**

- 23 **Objective:** To investigate the effectiveness of pulsed electromagnetic fields (PEMFs) for the
- 24 management of primary osteoporosis in older adults.
- 25 **Design:** Systematic review and meta-analysis.
- 26 **Data Sources:** MEDLINE, EMBASE, Web of Science, CENTRAL and CCTR, Physiotherapy
- 27 Evidence Database, CNKI, VIP, Wan Fang, ClinicalTrials.gov and Current controlled trials from
- 28 the inception dates to April 30, 2021.
- 29 **Eligibility criteria for study selection:** Randomised controlled trials or quasi-randomised trials
- 30 examining the effects of PEMFs compared to placebo or sham or other agents for the
- 31 management of primary osteoporosis (including those with previous fractures).
- 32 **Data extraction and synthesis:** Two independent reviewers extracted data. Primary outcomes
- 33 were bone mass and number of incident fractures. Secondary outcomes were functional
- 34 assessments, quality of life, and adverse events. Risk of bias was assessed with the Cochrane
- 35 Collaboration's tool and certainty of evidence with the grading of recommendations assessment,
- 36 development and evaluation (GRADE) framework. A random effects model was used to calculate
- 37 mean differences and 95% confidence intervals.
- 38 **Results:** Eight trials including 396 participants met the inclusion criteria. Low certainty evidence 39 showed that PEMFs was non-inferior to conventional pharmacological agents in preventing the 40 decline of Bone Mineral Density (BMD) at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur 41 neck (MD 0.01; CI -0.02 to 0.04), and improving balance function measured by Berg Balance
- 42 Scale (BBS) (MD 0.01; CI -0.09 to 0.11) and Timed Up and Go test (MD -0.04; CI -0.80 to 0.72),
- 43 directly after intervention. The similar effects were observed in BMD and BBS at 12- and 24-
- 44 weeks follow-up from baseline with moderate certainty evidence. Very low certainty evidence
- 45 showed that PEMFs (versus exercise) had small but significant effect on BMD at the femur neck
- 46 (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 to 0.35).
- 47 **Conclusion:** PEMFs had positive effects non-inferior to first-line treatment on BMD and balance
- 48 function in older adults with primary osteoporosis, but with low to very low certainty evidence
- 49 and short-term follow-ups. There is a need for high-quality randomised controlled trials
- 50 evaluating PEMFs for the management of primary osteoporosis.
- 51 **Registration:** PROSPERO CRD42018099518.
- 52

#### 53 **INTRODUCTION**

54 Osteoporosis is a systemic and multifactorial skeletal disorder characterized by low bone mineral 55 density and skeletal fragility that occur with aging, with a consequent increase of susceptibility to 56 low-trauma fractures  $\frac{1}{1}$ . The most prevalent symptoms of osteoporosis are fractures at vertebrae, 57 proximal femur (hip), and wrist affecting patients' physical function and quality of life. It is 58 estimated that over 200 million people worldwide are affected by osteoporosis, accounting for 8.9 59 million fractures annually  $\frac{2}{\pi}$ . The possibility of osteoporotic fractures exceeds 40% and the 60 probability of hip fracture alone could target 20% in white female population over 50 years old  $3$ . 61 In China, a higher incidence of hip fractures in men than in women was reported  $4$ . Each year, 62 osteoporotic fractures account for over 432,000 hospitalizations and 2.5 million medical visits in 63 the USA  $^5$ . The treatment costs for fractures were recorded at nearly \$17 billion in the USA in 64 2005<sup>6</sup>, and  $\epsilon$ 31.7 billion in Europe in 2000<sup>7</sup>. Therefore, osteoporosis has been identified as a 65 major health burden globally by WHO, due to its high prevalence, disability rate, related 66 mortality and poor quality of life  $8<sup>8</sup>$ .

67 Rehabilitation interventions given its important roles in modifying risk factors related to fractures, 68 restoring function and improving quality of life are frequently recommended as an option in the 69 nonpharmacological management of osteoporosis  $9,10$ . Pulsed electromagnetic fields (PEMFs) at a 70 specific intensity and frequency have been proved effective in attenuating bone loss and the relief 71 of pain and discomfort after osteoporosis. As we reviewed elsewhere  $11$ , PEMFs were found to be 72 positive at promoting bone formation by stimulating the formation and differentiation of 73 osteoblasts, and negative at inhibiting the function of osteoclasts in bone resorption. Experimental studies suggest that PEMFs may exert effects on  $Ca^{2+}$ -related receptors on the bone 75 cell membrane which play a regulatory role in the maintenance of bone remodelling  $12$ . Further, 76 the exposure of PEMFs could influence the physiopathology of osteoporosis by targeting 77 inflammation and potentially relieving pain via these regulatory processes and improvements in 78 bone remodeling  $^{13}$ .

79 PEMFs have been widely used as an clinical option for the management of pain and discomfort 80 related to osteoporosis since the introduce of its usage for non-union fractures was approved by 81 . FDA in 1979  $^{14}$ . However, clinical trials evaluating the effectiveness of PEMFs have been 82 conducted with inconsistent results, to which parameters of PEMFs used in studies, follow-up 83 time points and clinical settings differ across studies may lead  $11$ . In order to expand upon the

84 current knowledge on whether PEMFs is an effective physical agent for osteoporosis clinically, a

85 systematic review and meta-analysis of clinical trials was performed to compare PEMFs with

- 86 placebo or sham or other agents for the management of primary osteoporosis in older adults.
- 87

### 88 **METHODS**

89 This systematic review and meta-analysis was conducted in accordance with the Cochrane 90 Handbook for Systematic Reviews of Interventions<sup>15</sup> and reported based on Preferred Reporting 91 Items for Systematic Reviews and Meta-analyses guidelines (PRISMA)  $^{16}$ . The protocol of this 92 study is available in PROSPERO (CRD42018099518)  $^{17}$ .

93

### 94 **Identification and selection of studies**

95 We searched the MEDLINE (via Ovid), EMBASE (via Ovid), Web of Science, CENTRAL and 96 CCTR (via The Cochrane Library), Physiotherapy Evidence Database (via PEDro website), 97 CNKI, VIP, Wan Fang, ClinicalTrials.gov (https://www.clinicaltrials.gov/) and Current 98 controlled trials (www.controlled-trials.com) from the inception dates to December 9, 2018, 99 using the keywords *pulsed electromagnetic fields* and *osteoporosis*. The Open Grey 100 (http://www.opengrey.eu/) was searched for the Grey Literature research. The detailed electronic 101 search strategies are provided in Supplementary Appendix I. An additional search was performed 102 under a mechanism of living systematic review  $18$  to identify recently published randomized 103 clinical trials (RCTs) from December 10, 2018 to April 30, 2021 using the databases and 104 keywords described above. The whole procedure was assisted by a librarian from Sichuan 105 University.

106 Randomised controlled trials or quasi-randomised trials examining the effects of PEMFs 107 compared to placebo or sham or other agents for the management of primary osteoporosis 108 (including those with previous fractures) were included if they met the inclusion criteria listed in 109 Box 1. Studies were excluded if the study population had a diagnosis of corticosteroid-induced 110 osteoporosis or other secondary osteoporosis (e.g., rheumatoid arthritis), studies where 111 participants had a history of hip replacement or surgery related with osteoporotic fractures, the 112 study type was observational studies, review articles, abstracts, conference reports and book 113 chapters.

114 A three-stage screening methodology was performed to select relevant RCTs for this review.

115 Primarily, all titles were screened by one reviewer (SYZ) for eligibility and irrelevant papers 116 were excluded accordingly. Secondary, two reviewers (YL and LQW or KPS) independently 117 reviewed each study title and abstract. Thirdly, two independent reviewers (XNX and JMH or 118 XLG) accessed the full text to assess against the eligibility criteria for each potentially eligible 119 study. A third reviewer (CQH or LY) was involved for any disagreement.

120

#### 121 **Assessment of characteristics of studies**

#### 122 *Quality assessment*

123 The risk of bias was assessed by using the Cochrane Collaboration's 'Risk of bias' tool <sup>15</sup>. Seven 124 key domains were assessed by two reviewers (SYZ and LQW): 1) the randomization sequence 125 generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of 126 outcome assessment, 5) incomplete outcome data, 6) selective reporting, and 7) other bias. The 127 included studies were graded as low, unclear, or a high risk of bias. Methodological quality was 128 assessed with the use of Physiotherapy Evidence Database (PEDro) tool  $^{19}$ , which was proved 129 reliable  $20$  and valid  $21$ . Each criterion in the PEDro scale with a range of 0-10 was scored 1 130 ("yes") or 0 ("no, don't know/unclear"). Generally, trials with a PEDro summary score of over 131 five. were considered to have adequate methodological quality  $^{22}$ . Finally, we used Grading of 132 Recommendations, Assessment, Development and Evaluations (GRADE)<sup>23</sup> to describe the 133 overall quality of the body of evidence.

134

### 135 *Participants*

136 To be included, studies involved participants were healthy older adults (including those with 137 previous fractures) aged over 50 years with primary osteoporosis  $^{24}$ , recognized by two distinct 138 types  $2^5$ : 1) type I occurred in postmenopausal women; 2) type II, known as senile osteoporosis, 139 occurred in both men and women.

140

### 141 *Interventions*

142 All RCTs applying electromagnetic fields with pulsed signal and extremely low frequencies 143 (between 5 and 300 Hz) for the management of primary osteoporosis were included. The 144 parameters (frequency and intensity) of PEMFs, sessions per week and total duration of the 145 treatment period were recorded to describe the interventions.

146

#### 147 *Outcome measures*

148 All outcomes were continuous data and recorded as the percent change from baseline to post-149 intervention and different follow-up timepoints. To be included, trials had to provide original 150 data or sufficient information about at least one of outcomes on bone mass, number of incident 151 fractures, self-reported data on the changes in balance and quality of life, physical activity and 152 function, and adverse events. Primary outcomes were bone mass (e.g., Bone Marrow Density or 153 Bone Mineral Content) immediately post-intervention and at follow-ups, and number of incident 154 fractures. Secondary outcomes were functional assessments (e.g., Berg Balance Scale, Timed Up 155 and Go test), quality of life (e.g., EuroQoL (EQ 5D)) and adverse events (e.g., falls and death).

156

### 157 **Data extraction and analysis**

158 Two independent reviewers (SYZ and YL) extracted the following information from eligible 159 studies: lead author; year of publication; original country; subject characteristics; study design; 160 treatment information; intervention protocol; outcome measures; raw outcome data; follow-up 161 period and other relevant information. Disagreements were resolved by consensus.

162 All meta-analyses were performed using analysis was performed using Review Manager 163 (RevMan) software (The Cochrane Collaboration, version 5.4). For each included study, the 164 mean difference (MD) of percentage change with 95% confidential intervals (CIs) was calculated 165 when the outcome measures were consistent across studies or else the standard mean difference 166 (SMD) was calculated instead for continuous outcomes (reporting mean and standard deviation 167 (SD) or standard error (SE) of the mean). If the MD was not reported, it was calculated as the 168 change between values of the baseline and post-intervention. In the case that the value of SD 169 ( $SD_{diff}$ ) was not reported, it was obtained 1) by multiplying SEs of means by the square root of 170 the sample size when standard errors (SEs) of the means were reported, or 2) with SDs at the 171 baseline (SD<sub>baseline</sub>) and post-intervention SD (SD<sub>post</sub>) in addition to the within-groups bivariate 172 correlation coefficient (r)  $26$ :

$$
SD_{diff} = \sqrt{SD_{baseline}^2 + SD_{post}^2 - (2 \times r \times SD_{baseline} \times SD_{post})}
$$

173 The  $I^2$  statistic was employed for evaluating heterogeneity and a standard Chi<sup>2</sup> test was employed 174 for detecting whether significant heterogeneity existed. Heterogeneity was statistically significant

175 at P < 0.10 after due consideration of  $I^2$  statistic, of which a value greater than 50% was 176 considered substantial heterogeneity  $27$ . The random-effects model was applied where the 177 evidence of heterogeneity was found.

178 The comparison was established between PEMFs and placebo control or exercise in the meta-179 analysis. The subgroup analysis was conducted to detect the effectiveness relative to different 180 follow-up timepoints (postintervention; follow-up at 12, 24 weeks from baseline). To evaluate the 181 quality and consistency of pooled results, the sensitivity analysis was conducted by deleting each 182 included study. Where the data allowed, assessment of publication bias was performed. All tests 183 were two-tailed, and  $P < 0.05$  was considered statistically significant.

184

### 185 **RESULTS**

### 186 **Flow of studies through the review**

187 In total, 806 articles were identified by our search, of which 124 duplicate articles were removed. 188 Based on title and abstract screening, 632 of these articles were excluded. Full texts of 50 articles 189 were read, a further 42 articles were excluded, remaining 8 articles included in the data extraction 190 and analysis of the review (Figure 1)  $^{28-35}$ .

191

## 192 **Characteristics of studies**

193 *Quality* 

194 All included studies achieved PEDro scores over 5, among which five studies achieved the score 195 over 8 (Table 1)<sup>28,29,31-33</sup>. Of the 8 included studies, 2 studies were rated as 'low risk of bias' in all 195 over 8 (Table 1)<sup>28,29,31-33</sup>. Of the 8 included studies, 2 studies were rated as 'low risk of bias' in all domains<sup>31,32</sup>, and other studies were classified as 'unclear risk of bias' for at least 1 aspect or 196 domains<sup>31,32</sup>, and other studies were classified as 'unclear risk of bias' for at least 1 aspect or <br>197 'high risk of bias' for at least 2 aspects. In results of GRADE, the quality of the evidence for the 198 comparison between PEMFs versus placebo control was low or moderate, and that for the 199 comparison between PEMFs versus exercise was very low. The results of the risk of bias and 200 GRADE are presented in the Supplementary Tables and Figures.

201

## 202 *Participants*

203 In total, data were extracted for 396 participants, comprising 183 participants in PEMFs group 204 and 213 participants in placebo control (alendronate/pharmacological therapy) or exercise group.

205 Mean age ranged from 56.3 to 70 years, with a gender ratio of 49 to 347. Participant 206 characteristics are detailed in Table 2.

207

#### 208 *Intervention*

209 The frequency and intensity of PEMFs exposure varied at 8-100 Hz and 1.2-5 mT separately. A 210 range of 30-36 PEMFs sessions, with 30-60 min/session, were prescribed for participants, and 4 211 to 72 weeks follow-up were conducted across all studies. Control intervention types included 212 first-line pharmacological agents (e.g., Alendronate, intake of Vitamin D and Calcium) and 213 exercise (e.g., whole body vibration and resistance training). The intervention characteristics of 214 the included studies are detailed in the Table 2.

215

### 216 *Outcome measures*

217 The outcome measures in each study with the categories of bone mass and functional assessments 218 are detailed in Table 2.

219

### 220 **Effect of intervention I: PEMFs versus control group**

### 221 *Bone Mineral Density (BMD)*

222 Five studies (study population,  $N=248$ ) <sup>28,30-33</sup> and three studies (study population, N=124)  $223$ <sup>30,32,33</sup> reported data on percentage change in BMD at the lumbar and femur neck respectively 224 after intervention directly (Figure 2). Low certainty evidence showed that PEMFs has no effect 225 on BMD at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur neck (MD 0.01; CI -0.02 to 0.04) 226 with no statistically significant heterogeneity (lumbar:  $I^2 = 0$ %, P =0.48; femur neck:  $I^2 = 0$ %, P = 227 0.79). Two studies (study population,  $N=125$ )  $^{31,32}$  performed follow-ups at 12 and 24 weeks from 228 baseline on percentage change in BMD at the lumbar (Figure 2). Moderate certainty evidence 229 showed that there is no statistically significant effect on BMD at the lumbar at the 12 weeks 230 follow-up (MD -0.01; CI -0.28 to 0.25) and the 24 weeks follow-up (MD -0.02; CI -0.30 to 0.26) 231 with no statistically significant heterogeneity (12 weeks:  $I^2 = 0\%$ , P = 1.00; 24 weeks:  $I^2 = 0\%$ , P 232 = 0.98). No significant changes in heterogeneity and overall effect were observed in the 233 sensitivity analysis.

234

### 235 *Berg Balance Scale (BBS)*

236 Three studies (study population,  $N=168$ )  $^{31,32,35}$  conducted the assessment of BBS after 237 intervention directly (Figure 3). Low certainty evidence showed that there is no statistically 238 significant effect on percentage change in BBS (MD 0.01; CI -0.09 to 0.11) with no statistically 239 significant heterogeneity ( $I^2 = 0\%$ ,  $P = 1.00$ ). Two studies (study population, N=125) <sup>31,32</sup> carried 240 out follow-ups at 12 and 24 weeks from baseline on percentage change in BBS (Figure 3). 241 Moderate certainty evidence showed that no statistically significant effect is detected on BBS at 242 the 12 weeks (MD 0.00; CI -0.13 to 0.14) and 24 weeks follow-up (MD -0.00; CI -0.15 to 0.14) 243 with evidence of no statistically significant heterogeneity (12 weeks:  $P = 0\%$ ,  $P = 0.99$ ; 24 weeks:  $244$  I<sup>2</sup> = 0%, P = 0.99). No significant changes in heterogeneity and overall effect were observed in 245 the sensitivity analysis.

246

## 247 *Timed Up and Go (TUG) test*

248 Two studies (study population,  $N=127$ )  $^{31,35}$  assessed the percentage change in TUG test after 249 intervention directly (Figure 3). Low certainty evidence showed that there is no statistically 250 significant effect on TUG (MD -0.04; CI -0.80 to 0.72) with no statistically significant 251 heterogeneity ( $I^2 = 0\%$ ,  $P = 0.97$ ). No significant changes in heterogeneity and overall effect were 252 observed in the sensitivity analysis.

253

## 254 **Effect of intervention II: PEMFs versus exercise group**

255 Three studies (study population, N=110) <sup>29,33,34</sup> investigated the effect of PEMFs on percentage 256 change in BMD at the lumbar and femur neck respectively after intervention directly (Figure 4). 257 Very low certainty evidence showed that PEMFs has small but significant effect on BMD at the 258 femur neck (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 259 to 0.35), both with no statistically significant heterogeneity respectively (femur neck:  $I^2 = 28\%$ , P  $260 = 0.25$ ;  $P = 47\%$ ,  $P = 0.15$ ). In the sensitivity analysis, one study <sup>29</sup> was found to be a contributor 261 to results of non-significant heterogeneity and the effect on BMD at the femur neck. After 262 excluding the study, the heterogeneity was reduced to 0% (femur neck:  $P = 0.96$ ;  $P = 0.86$ ), and 263 the small but significant effect on BMD at the femur neck was eliminated (MD 0.00; CI -0.15 to 264 0.16).

265

### 266 **DISCUSSION**

267 This systematic review and meta-analysis of 8 studies involving 396 participants demonstrated 268 PEMFs as a physical therapy was non-inferior to conventional pharmacological agents in 269 preventing the decline of BMD and balance function for the management of primary osteoporosis 270 in older adults. Meanwhile, we also found that PEMFs might be slightly more effective in 271 increasing BMD than exercise. According to our knowledge, no systematic review and meta-272 analysis was initiated before, except one network meta-analysis exploring effects of 273 nonpharmacological interventions including PEMFs on balance function only  $36$ , and several 274 narrative reviews including clinical studies were retrieved  $11,37,38$ . Our results are in consistent 275 with findings from previous reviews<sup>11,36,37</sup> that PEMFs achieved positive effects on BMD and 276 balance function for older adults with primary osteoporosis, implicating that PEMFs may 277 potentially become a promising treatment option.

278 Bisphosphonates and exercise were both identified as the first-line interventions for the 279 management of osteoporosis in the latest evidence-based guideline  $10$ . Our study established 280 comparisons between PEMFs and active placebo or exercise based on groups set by included 281 studies, and sub-group analysis was stratified by different intervals between the baseline, post-282 intervention, and follow-ups. BMD, as a surrogate measure for therapeutic effectiveness, can be 283 assessed by various methods, among which dual x-ray absorptiometry (DXA) was proved to be 284 reliable in the diagnosis of osteoporosis and have relatively good responsiveness in RCT  $^{39,40}$ . 285 Our study demonstrated that there was no difference between PEMFs and active placebo in 286 improving BMD at the lumbar and femur neck in all sub-group meta-analysis, which suggests 287 PEMFs is nearly effective as pharmacological agents for osteoporosis, and the effect could last 288 for at least 24 weeks. Moreover, the effects of PEMFs versus exercise on BMD at the lumbar was 289 not significant, while that was detected as small but significant on BMD at the femur neck. Our 290 results were considered fairly stable as the sensitivity analysis only detected one study <sup>29</sup> affecting 291 the heterogeneity and effect of PEMFs versus exercise on BMD at the femur neck. This is likely 292 due to variations in exercise characteristics (e.g., duration, training load and training volume). 293 Therefore, this part of results should be interpreted with caution.

294 Impaired balance function is an important risk factor increasing the incidence of falling and 295 fracture, which is modifiable by balance-improving interventions  $41$ . In line with results on BMD, 296 no statistically significant difference was observed for balance function measured by BBS and 297 TUG after the intervention of PEMFs versus active placebo. In the sub-group analysis, the effect

298 of PEMFs on BBS at 12, 24 weeks follow-up was also not statistically significant, confirming 299 that PEMFs is as effective as conventional pharmacological agents in improving balance function 300 which could last for 24 weeks. In consistent with a previous systematic review  $36$ , it reported that 301 PEMFs exert positive effect on BBS and TUG tests reflecting balance function. However, the 302 network meta-analysis was conducted to further compare the effects of five interventions on 303 balance function with the conclusion that balance and strength training was better than other 304 interventions. Only one study using data on PEMFs was included in the analysis, compared to 305 that we included 3 studies, and no study was ever conducted to directly compare the effect of 306 PEMFs versus other non-pharmacological interventions on balance function, combining these 307 two may explain, in part, the conflicting results. Furthermore, our sensitivity analysis detecting 308 no changes in levels of heterogeneity and effect confirmed our results as relatively robust.

309 To overcome the shortcomings of the "statistically significant difference", the minimum 310 clinically important difference (MCID) defined as "the smallest change that is important to 311 patients" is employed to generate a threshold value for such change  $42$ . Any patient whose 312 responses help them reach the MCID threshold is considered as responders. Thus, a certain 313 proportion of responders to the total participants involved in a trialed intervention indicates the 314 likelihood of patients under the same condition also responding favorably to the same  $315$  intervention  $43$ . However, no definite consensus reached on the MCID of BMD and balance 316 function. Some evidence showed that changes by 2-5% at the lumbar and 8% at the proximal  $f(317)$  femur <sup>44</sup>, a point-drop in BBS associated with a 3-4% increase in risk of falling <sup>45</sup>, and an 318 improvement of 2-3 seconds in TUG test were considered as MCID for the older population  $^{46}$ . In 319 our study, no study included used the MCID and responder rate to evaluate the effect of PEMFs, 320 thus, it is hard to determine the clinical importance of improvements achieved by PEMFs on 321 BMD and balance function compared with placebo and exercise. Furthermore, the successful 322 treatment of osteoporosis is prevention of fractures, while no treatment can completely eliminate 323 fracture risk  $10$ . Although a certain increase in BMD and the improvement in balance function for 324 osteoporosis may result in a reduction in fracture risk, no risk and number of incident fracture 325 were reported in studies included in our review. Therefore, studies with reporting measures of 326 MCID, fracture risk and incidence in the future are required to further confirm that the effect of 327 PEMFs in treating osteoporosis is of clinical importance to clinicians and patients.

328 This review has several strengths. To date, we are the first to conduct a systematic review and

329 meta-analysis to explore the effect of PEMFs on BMD and balance function for primary 330 osteoporosis. Secondary, the results of our study were fairly stable due to studies included were 331 of appropriate methodological quality, and no significant heterogeneity was found in the analysis. 332 Furthermore, a key finding of this review was that PEMFs as an intervention alone achieved an 333 effect non-inferior to first-line treatment (pharmacological agents and exercise) on improvements 334 in BMD and balance function for older adults with primary osteoporosis. At last, a librarian 335 familiar with the development of searches and a mechanism of living systematic review were 336 involved over a course of 3 years to ensure no study was missed in compliance with the study 337 protocol.

338 There are several limitations to this review that deserve consideration. The primary limitation of 339 our review was the limited number of included studies with only 8 studies comprising of 396 340 participants for the analysis, from which the level of evidence generated were moderate to very 341 low. In some sub-group analyses, only 2-3 studies were included from which some uncertainty in 342 the results interpretation may exist based on data extracted. In addition, as the maximum PEMF 343 treatment session lasted for 16 weeks and the longest follow-up was 24 weeks for the analysis, 344 the error among the minimum percentage change in BMD and balance function may stay 345 undetectable and further deepened the uncertainty  $44$ . Furthermore, the clinical relevance of the 346 findings was limited, combined with no study reported data on MCID, responder rate and 347 incident fracture and only two studies  $31,32$  included used intention-to-treat (ITT) analysis.  $348$  According to accumulated evidence  $11,47$ , the parameters of non-pharmacological interventions, 349 including intensity, frequency, and duration, were critical to impact changes in outcome measures 350 for osteoporosis, while our study could not conduct the sub-group analysis based on different 351 parameters due to limited information retrieved. Another potential limitation was the systematic 352 search was limited to English and Chinese manuscripts available in full text, and some relevant 353 trials may be missed.

354

### 355 **CONCLUSION**

356 In summary, moderate to very low certainty evidence showed that PEMFs as an intervention 357 alone has positive effects non-inferior to first-line treatment (pharmacological agents and exercise) 358 on BMD and balance function in older adults with primary osteoporosis and should be considered 359 as a promising option in the management of osteoporosis. Although uncertainty about responses

360 to the intervention and changes in outcome measures may be existed but undetectable, our 361 findings may still be fairly stable as we consistently found similar results in the primary and 362 sensitivity analyses. For further deeply confirming the effect of PEMFs for osteoporosis, adding 363 endpoints like fracture risk and incidence, and outcome measures like MCID and responder rate 364 to the core collection are necessary. In the future, researchers planning a PEMFs study should 365 optimize the study design, with taking factors not limited to undetectable errors under outcomes, 366 parameters of interventions, longer follow-up period, larger sample size and ITT analysis into 367 consideration, to generate high certainty evidence.

368

## 369 **DECLARATIONS**

370

### 371 **Acknowledgements**

372 We are grateful for the partnership and support from the library of Sichuan University for the

373 development of search strategy, also and the clinical research and statistics office of West China

- 374 Hospital for data processing and analysis.
- 375

## 376 **Funding**

377 This study was supported by the National Natural Science Foundation (81972146 to Chengqi He,

378 and 82002393 to Siyi Zhu), the Department of Science and Technology of Sichuan Province

379 (2020YJ0210 to Chengqi He, 2021YFS0004 and 2021YJ0424 to Siyi Zhu), China Postdoctoral

380 Science Foundation (2020M673251), Health Commission of Sichuan Province (20PJ034), and

381 West China Hospital of Sichuan University (2019HXBH058 to Siyi Zhu). The funders played no

382 role in the design, conduct, or reporting of this study.

383

# 384 **Availability of Data and Materials**

- 385 Not applicable
- 386
- 387 **Authors' contributions**
- 388 All authors have made substantial contributions to the study design. SYZ and YL have
- 389 contributed to the ongoing data collection. All listed authors have contributed to the drafting of
- 390 the manuscript.

### 391

## 392 **Competing interests**

- 393 The authors declare that they have no competing interests.
- 394

## 395 **REFERENCES**

- 396 1. Eastell R, O'Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. *Nature reviews*  397 *Disease primers.* 2016;2:16069.
- 398 2. International Osteoporosis Foundation. EPIDEMIOLOGY OF OSTEOPOROSIS AND 399 FRAGILITY FRACTURES. https://www.osteoporosis.foundation/facts-400 statistics/epidemiology-of-osteoporosis-and-fragility-fractures. Published 2021. Accessed 401 May 12, 2021.
- 402 3. Bessette L, Ste-Marie L-G, Jean S, et al. The care gap in diagnosis and treatment of 403 women with a fragility fracture. *Osteoporosis International.* 2008;19(1):79-86.
- 404 4. International Osteoporosis Foundation. KEY STATISTICS FOR ASIA. 405 https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-asia. Published 2021. 406 Accessed May 12, 2021.
- 407 5. US D. Bone health and osteoporosis: A Report of the Surgeon General. *http://www* 408 *surgeongeneral gov/library/bonehealth/content html.* 2004.
- 409 6. Burge R, Dawson Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis  $\Box$  related fractures in the United States, 2005–2025 410 and economic burden of osteoporosis□related fractures in the United States, 2005–2025.<br>411 Journal of bone and mineral research. 2007;22(3):465-475. 411 *Journal of bone and mineral research.* 2007;22(3):465-475.
- 412 7. Kanis J, Johnell O. Requirements for DXA for the management of osteoporosis in 413 Europe. *Osteoporosis international.* 2005;16(3):229-238.
- 414 8. Kanis J, Group WS. Assessment of Osteoporosis at the Primary Health Care Level. 415 Geneva. *World Health Organization.* 2008.
- 416 9. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *Pharmacy*  417 *and Therapeutics.* 2018;43(2):92.
- 418 10. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical 419 Endocrinologists/American College of Endocrinology clinical practice guidelines for the 420 diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocrine*  421 *Practice.* 2020;26:1-46.
- 422 11. Zhu S, He H, Zhang C, et al. Effects of pulsed electromagnetic fields on postmenopausal 423 osteoporosis. *Bioelectromagnetics.* 2017;38(6):406-424.
- 424 12. Petecchia L, Sbrana F, Utzeri R, et al. Electro-magnetic field promotes osteogenic 425 differentiation of BM-hMSCs through a selective action on Ca 2+-related mechanisms. 426 *Scientific reports.* 2015;5:13856.
- 427 13. Vincenzi F, Targa M, Corciulo C, et al. Pulsed electromagnetic fields increased the anti-428 inflammatory effect of A2A and A3 adenosine receptors in human T/C-28a2 429 chondrocytes and hFOB 1.19 osteoblasts. *PloS one.* 2013;8(5):e65561.
- 430 14. Andrew C, Bassett L, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively 431 coupled electromagnetic fields. *Science.* 1974;184(4136):575-577.
- 432 15. Higgins JP, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of*  433 *interventions.* John Wiley & Sons; 2019.
- 434 16. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated 435 guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.



483 *back and musculoskeletal rehabilitation.* 2017;30(4):903-912. 484 34. Shanb A-SA, Youssef EF, El-Barkouky MG, Kamal RM, Tawfick AM. The effect of 485 magnetic therapy and active exercise on bone mineral density in elderly women with 486 osteoporosis. *Journal of Musculoskeletal Research.* 2012;15(03):1250016. 487 35. Wu Y-C, Xu J, Yang L, Xiong E-F, Xie W, He C-Q. The effect of low-frequency pulsed 488 electromagnetic fields on balance ability of patients with post-menopausal osteoporosis. 489 *Sichuan da xue xue bao Yi xue ban= Journal of Sichuan University Medical science*  490 *edition.* 2014;45(1):116-119. 491 36. Zhu L, Wu W, Chen M, et al. Effects of Nonpharmacological Interventions on Balance 492 Function in Patients with Osteoporosis or Osteopenia: A Network Meta-Analysis of 493 Randomized Controlled Trials. *Evidence-Based Complementary and Alternative*  494 *Medicine.* 2021;2021. 495 37. Wang R, Wu H, Yang Y, Song M. Effects of electromagnetic fields on osteoporosis: a 496 systematic literature review. *Electromagnetic biology and medicine.* 2016;35(4):384-390. 497 38. Wang T, Yang L, Jiang J, et al. Pulsed electromagnetic fields: promising treatment for 498 osteoporosis. *Osteoporosis International.* 2019;30(2):267-276. 499 39. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and 500 treatment of osteoporosis. *Postgraduate medical journal.* 2007;83(982):509-517. 501 40. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of 502 osteoporosis. *Journal of bone and mineral research.* 1994;9(8):1137-1141. 503 41. Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a 504 systematic review of recent 10 years and meta-analysis. *Journal of the American Medical*  505 *Directors Association.* 2012;13(2):188. e113-188. e121. 506 42. Stratford PW, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to change of the Roland-507 Morris back pain questionnaire: part 1. *Physical therapy.* 1998;78(11):1186-1196. 508 43. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically 509 important difference in pain outcome measures. *Pain.* 2000;88(3):287-294. 510 44. Cranney A, Welch V, Wells G, et al. Discrimination of changes in osteoporosis outcomes. 511 *The Journal of rheumatology.* 2001;28(2):413-421. 512 45. Shumway-Cook A, Baldwin M, Polissar NL, Gruber W. Predicting the probability for 513 falls in community-dwelling older adults. *Physical therapy.* 1997;77(8):812-819. 514 46. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for 515 frail elderly persons. *Journal of the American geriatrics Society.* 1991;39(2):142-148. 516 47. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in 517 postmenopausal women. *Cochrane Database of Systematic Reviews.* 2002(2). 518 519

- 520 Box of inclusion criteria for eligible studies
- 521

#### **Box 1.** Inclusion criteria

523

- Design
	- Randomised or quasi-randomised controlled trial
	- Published in a peer-reviewed journal
	- Full text available in Chinese and English

#### **Participants**

• Healthy older adults (including those with previous fractures) aged over 50 years with primary osteoporosis

#### Intervention

- Electromagnetic fields with pulsed signal and extremely low frequencies (between 5 and 300 Hz) Outcome measures
	- Primary outcomes: bone mass, number of incident fractures
	- Secondary outcomes: Functional assessments, quality of life, adverse events

#### **Comparisons**

- PEMFs versus sham/nothing
- PEMFs versus placebo/pharmacological agents
- PEMFs versus exercise/other physical agent or intervention
- PEMFs plus other intervention versus other intervention

524 525 526

## **Table 1**

PEDro scores of included studies.



## **Table 2**

Characteristics of the included studies.





<sup>a</sup>Waveforms; Intensity; Frequency; Duration (weeks).<br><sup>b</sup>Abbreviations. PEMFs=Pulsed electromagnetic fields, AL=alendronate, WBV=Whole body vibration, CRT=Circuit weight training, LLLT=low-level laser therapy, mT=millitesla, Hz=Hertz, BMDL=lumbar bone mineral density, BMDF=femur bone mineral density, 25(OH)D=serum 25OH vitamin, LE MMT=total lower-extremity manual muscle test, BBS=Berg Balance Scale, VAS=Visual Analogue Scale, N/A=not applicable, TUG=Timed Up and Go, ALP=Alkaline Phosphatase, PICP=Procollagen type I carboxy-terminal propeptide, Med=Medication.



Figure 1. PRISMA flow of studies through the review.



**Figure 2.** Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.



Test for subaroup differences: Not applicable

Figure 3. Forest plot analysis of the effects of PEMFs on balance function measured by BBS (A) and TUG test (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BBS = Berg Balance Scale; TUG = Timed Up and Go; PEMFs = Pulsed Electromagnetic Fields.





**Figure 4.** Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with exercise group. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.